LLY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LLY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eli Lilly and Co's total inventories for the quarter that ended in Dec. 2024 was $7,589 Mil. Eli Lilly and Co's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $7,525 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Eli Lilly and Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-54.65.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Eli Lilly and Co's Days Inventory for the three months ended in Dec. 2024 was 285.64.
Inventory Turnover measures how fast the company turns over its inventory within a year. Eli Lilly and Co's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.32.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Eli Lilly and Co's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.56.
The historical data trend for Eli Lilly and Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
3,980.30 | 3,886.00 | 4,309.70 | 5,772.80 | 7,589.20 |
Eli Lilly and Co Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
5,772.80 | 6,101.80 | 6,481.50 | 7,459.80 | 7,589.20 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Eli Lilly and Co (NYSE:LLY) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Eli Lilly and Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is
Net-Net Working Capital Per Share (Q: Dec. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (3423.2 | + | 0.75 * 11005.7 | + | 0.5 * 7589.2 | - | 64443.3 |
- | 0 | - | 79.5) | / | 897.538 | ||
= | -54.65 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Eli Lilly and Co's Days Inventory for the three months ended in Dec. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2024 ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | 7524.5 | / | 2403.8 | * | 365 / 4 | |
= | 285.64 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Eli Lilly and Co's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2024 ) | / | Average Total Inventories (Q: Dec. 2024 ) |
= | 2403.8 | / | 7524.5 | |
= | 0.32 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Eli Lilly and Co's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 7524.5 | / | 13532.8 | |
= | 0.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Eli Lilly and Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Donald A Zakrowski | officer: Chief Accounting Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Lilly Endowment Inc | 10 percent owner | 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208 |
Daniel Skovronsky | officer: SVP, CSO, and Pres. LRL | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Johna Norton | officer: Senior VP, Global Quality | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Alonzo Weems | officer: SVP, ERM & CECO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Patrik Jonsson | officer: SVP and Pres., Lilly Bio-Meds | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Anne E. White | officer: SVP & Pres-Lilly Oncology | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Eric Dozier | officer: EVP, HR & Diversity | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jackson P Tai | director | |
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Marschall S Runge | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Naarden Jacob Van | officer: SVP, CEO LoxoONC, Pres LlyONC | C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Diogo Rau | officer: SVP & CIDO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Edgardo Hernandez | officer: SVP & Pres., Mfg. Operations | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Kimberly H Johnson | director | C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005 |
From GuruFocus
By GuruFocus News • 02-22-2025
By GuruFocus News • 02-25-2025
By GuruFocus News • 02-23-2025
By GuruFocus News • 03-03-2025
By GuruFocus News • 02-25-2025
By GuruFocus News • 03-20-2025
By GuruFocus News • 02-26-2025
By GuruFocus News • 03-10-2025
By GuruFocus News • 02-28-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.